Ultrasound in medicine & biology · 2022
Application of Deep Learning to Reduce the Rate of Malignancy Among BI-RADS 4A Breast Lesions Based on Ultrasonography.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Zhijin, Hou Size, Li Shuang, Sheng Danli, Liu Qi, Chang Cai, Chen Jiangang, Li Jiawei
Аннотация
The aim of the work described here was to develop an ultrasound (US) image-based deep learning model to reduce the rate of malignancy among breast lesions diagnosed as category 4A of the Breast Imaging-Reporting and Data System (BI-RADS) during the pre-operative US examination. A total of 479 breast lesions diagnosed as BI-RADS 4A in pre-operative US examination were enrolled. There were 362 benign lesions and 117 malignant lesions confirmed by postoperative pathology with a malignancy rate of 24.4%. US images were collected from the database server. They were then randomly divided into training and testing cohorts at a ratio of 4:1. To correctly classify malignant and benign tumors diagnosed as BI-RADS 4A in US, four deep learning models, including MobileNet, DenseNet121, Xception and Inception V3, were developed. The performance of deep learning models was compared using the area under the receiver operating characteristic curve (AUROC), accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Meanwhile, the robustness of the models was evaluated by five-fold cross-validation. Among the four models, the MobileNet model turned to be the optimal model with the best performance in classifying benign and malignant lesions among BI-RADS 4A breast lesions. The AUROC, accuracy, sensitivity, specificity, PPV and NPV of the optimal model in the testing cohort were 0.897, 0.913, 0.926, 0.899, 0.958 and 0.784, respectively. About 14.4% of patients were expected to be upgraded to BI-RADS 4B in US with the assistance of the MobileNet model. The deep learning model MobileNet can help to reduce the rate of malignancy among BI-RADS 4A breast lesions in pre-operative US examinations, which is valuable to clinicians in tailoring treatment for suspicious breast lesions identified on US.